• Facets (new session)
• Description
• Metadata
• Settings
  • Rule: ActivityStreamsMapasEquivalentb3sb3sifpdbprdf-labelfacetshttp://dbpedia.org/resource/inference/rules/dbpedia#http://dbpedia.org/resource/inference/rules/opencyc#http://dbpedia.org/resource/inference/rules/umbel#http://dbpedia.org/resource/inference/rules/yago#http://dbpedia.org/schema/property_rules#http://www.ontologyportal.org/inference/rules/SUMO#http://www.ontologyportal.org/inference/rules/WordNet#http://www.w3.org/2002/07/owl#ldpoplwebskos-transurn:det:rdf:labelvirtrdf-labelvirtrdf-urlNone
    
  • Inverse Functional Properties: Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects
  • "Same As": Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects (recommended) Apply to subjects, objects and predicates (not recommended on big datasets) Apply to predicates only (special use cases only)

About: Tetrabamate     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : yago:Tranquilizer104470232, within Data Space : dbpedia.demo.openlinksw.com associated with source document(s)

Type: Thingdul:ChemicalObjectchemical substanceDrugyago:WikicatAnxiolyticsyago:WikicatBarbituratescombination drugyago:WikicatCombinationDrugsyago:WikicatMuscleRelaxantsyago:WikicatWithdrawnDrugsyago:WikicatSedativesyago:Agent114778436yago:Barbiturate102792049yago:CausalAgent100007347yago:Drug103247620yago:DrugOfAbuse103248958yago:Matter100020827yago:Medicine103740161yago:MinorTranquilizer103771443yago:MuscleRelaxant103800001yago:PhysicalEntity100001930yago:PsychotropicAgent104017429yago:Relaxant104072811drugyago:Sedative-hypnotic104166841yago:Sedative104166553yago:Substance100020090yago:Tranquilizer104470232 New Facet based on Instances of this Class

Tetrabamate (Atrium, G Tril, Sevrium) is a combination drug formulation of febarbamate, difebarbamate, and phenobarbital which was marketed in France and Spain and was used to treat anxiety and alcohol withdrawal-associated muscle tremors, agitation, and depression. It was largely, but not completely discontinued on April 4, 1997 after over 30 years of use due to reports of hepatitis and acute liver failure. The decision to restrict the use of the drug had been long-awaited.